BioLineRx Stock Scheduled to Reverse Split on Thursday, January 30th (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) shares are set to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.

BioLineRx Stock Up 3.4 %

BLRX opened at $0.11 on Wednesday. The company has a fifty day moving average price of $0.25 and a 200-day moving average price of $0.48. The firm has a market capitalization of $8.39 million, a P/E ratio of -0.48 and a beta of 1.46. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. BioLineRx has a one year low of $0.08 and a one year high of $1.44.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Equities research analysts expect that BioLineRx will post -0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on BLRX. HC Wainwright cut their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com began coverage on shares of BioLineRx in a research report on Sunday. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atria Investments Inc lifted its stake in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. PVG Asset Management Corp bought a new stake in BioLineRx in the second quarter worth $70,000. Finally, CVI Holdings LLC bought a new stake in BioLineRx in the second quarter worth $462,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.